"Omalizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA.
| Descriptor ID |
D000069444
|
| MeSH Number(s) |
D12.776.124.486.485.114.071.500 D12.776.124.486.485.114.224.060.844 D12.776.124.790.651.114.071.500 D12.776.124.790.651.114.224.060.844 D12.776.377.715.548.114.071.500 D12.776.377.715.548.114.224.200.844
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Omalizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Anti-Idiotypic [D12.776.124.486.485.114.071]
- Omalizumab [D12.776.124.486.485.114.071.500]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Omalizumab [D12.776.124.486.485.114.224.060.844]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Anti-Idiotypic [D12.776.124.790.651.114.071]
- Omalizumab [D12.776.124.790.651.114.071.500]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Omalizumab [D12.776.124.790.651.114.224.060.844]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Anti-Idiotypic [D12.776.377.715.548.114.071]
- Omalizumab [D12.776.377.715.548.114.071.500]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Omalizumab [D12.776.377.715.548.114.224.200.844]
Below are MeSH descriptors whose meaning is more specific than "Omalizumab".
This graph shows the total number of publications written about "Omalizumab" by people in this website by year, and whether "Omalizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 15 | 5 | 20 |
| 2018 | 16 | 5 | 21 |
| 2019 | 13 | 4 | 17 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Omalizumab" by people in Profiles.
-
Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19. Dermatol Ther. 2021 11; 34(6):e15111.
-
Omalizumab prevents anaphylactoid reactions to mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021 Nov; 35(11):e743-e745.
-
Angioedema: differential diagnosis and acute management. Postgrad Med. 2021 Sep; 133(7):765-770.
-
Anti-IgE monoclonal antibodies as potential treatment in COVID-19. Immunopharmacol Immunotoxicol. 2021 Jun; 43(3):259-264.
-
Pediatric asthma control during the COVID-19 pandemic. Immun Inflamm Dis. 2021 06; 9(2):561-568.
-
The impact of COVID-19 pandemic on the management of patients with chronic urticaria: An observational two-center study from Turkey. Dermatol Ther. 2021 Jan; 34(1):e14652.
-
COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases. Int J Dermatol. 2021 Feb; 60(2):253-254.
-
Comment on "Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab". Int J Dermatol. 2020 11; 59(11):1417-1418.
-
Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab. Int J Dermatol. 2020 Oct; 59(10):1294-1295.
-
What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2? Dermatol Ther. 2020 11; 33(6):e14068.